Edesa Biotech, Inc. (EDSA)

[goforthebet]

Everyone is just talking about eb05 against ARDS but I've been doing a little Dd about eb06, too, which seems pretty promising as well. I'd love to get an update for that drug before the interim results. Eb06 is an antibody against the cxcl10 receptor and here is what I found out about cxcl10:

CXCL10 was recently identified as the cardinal chemokine playing a crucial role in COVID-19 being a chemoattractant for monocytes/macrophages, dendritic cells, NK cells, and T cells. Elevated serum levels of CXCL10 were consistently reported in patients with COVID-19, being positively correlated (together with CCL2) with increased disease severity and, more importantly with an increased risk of mortality. High levels of CXCL10 were previously reported to be associated also with the severe acute respiratory syndrome (SARS) disease progression and to the development of ARDS in preclinical models.

https://www.frontiersin.org/articles/10.3389/fimmu.2021.668507/full

apparently eb06 is in phase II, too. How come we don't know anything about that drug? It might even be possible to use eb06 as an add-on-drug for eb05, if a patient does not fully recover with eb05 only, because both drugs use different pathways to prevent the cytokine storm. Just imagine both drugs get an approval until the end of this year! Good times ahead, boys and girls



from Spottford STW